Discodermolide

Discodermolide (NVP-XAA-296) is a potent microtubule-stabilizing agent with a Ki of 0.4 μM. Discodermolide stabilizes microtubules, induces G2 or M phase cell cycle arrest and apoptosis, leading to inhibition of cancer cell proliferation. Discodermolide competitively inhibits the binding of Paclitaxel (HY-B0015) to tubulin polymers, and inhibits the growth of Paclitaxel-resistant cells. Discodermolide can be used for breast and colon cancer research[1][2][3].

Product Specifications

CAS Number

[127943-53-7]

Product Name Alternative

NVP-XAA-296; XAA 296

UNSPSC

12352005

Target

Apoptosis; Microtubule/Tubulin

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

C=C/C=C\[C@H](C)[C@H](OC(N)=O)[C@@H](C)[C@H](O)[C@@H](C)C/C(C)=C\[C@H](C)[C@@H](O)[C@@H](C)/C=C\[C@@H](O)C[C@H](O1)[C@@H]([C@@H]([C@@H](C)C1=O)O)C

Molecular Formula

C33H55NO8

Molecular Weight

593.79

References & Citations

[1]Altmann KH. Microtubule-stabilizing agents: a growing class of important anticancer drugs. Curr Opin Chem Biol. 2001 Aug;5 (4) :424-31.|[2]Kowalski RJ, et al. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol. 1997 Oct;52 (4) :613-22.|[3]Hung DT, et al. (+) -Discodermolide binds to microtubules in stoichiometric ratio to tubulin dimers, blocks taxol binding and results in mitotic arrest. Chem Biol. 1996 Apr;3 (4) :287-93.